Home/Rare Diseases/Multiple System Atrophy

Neurological & Neuromuscular

Multiple System Atrophy

Also called MSA, Shy-Drager syndrome

Multiple system atrophy (MSA) is a rare, progressive neurodegenerative disorder characterized by degeneration of neurons in the brain regions controlling the autonomic nervous system and movement. The disease presents with combinations of parkinsonian features (rigidity, bradykinesia), cerebellar ataxia (incoordination, gait disturbance), and autonomic failure (orthostatic hypotension, urinary incontinence, sexual dysfunction).

...active trials

Live from ClinicalTrials.gov

View trials below

About trials for Multiple System Atrophy

Clinical trials for MSA are evaluating neuroprotective therapies, anti-inflammatory agents, and approaches targeting alpha-synuclein pathology. The Multiple System Atrophy Coalition and patient registries maintain trial information.

Try Match Me →

About Multiple System Atrophy

Multiple system atrophy (MSA) is a rare, progressive neurodegenerative disorder characterized by degeneration of neurons in the brain regions controlling the autonomic nervous system and movement. The disease presents with combinations of parkinsonian features (rigidity, bradykinesia), cerebellar ataxia (incoordination, gait disturbance), and autonomic failure (orthostatic hypotension, urinary incontinence, sexual dysfunction). Pathological hallmark is neuronal inclusions containing alpha-synuclein protein. The disease progresses relentlessly, with median survival of about 10 years from symptom onset. Early symptoms are often autonomic dysfunction and sleep problems; motor symptoms develop progressively. Currently, there is no disease-modifying treatment, so management is symptomatic, focusing on blood pressure management, movement disorder treatment, and supportive care.

Common Symptoms

  • Orthostatic hypotension (dizziness when standing)
  • Parkinsonism or cerebellar ataxia
  • Vocal tremor and speech difficulty
  • Erectile dysfunction in men
  • Incontinence and urinary dysfunction
  • Sleep disturbances and REM sleep behavior disorder

Who It Affects

Typically manifests ages 50-60 years; median lifespan about 10 years from symptom onset. Affects males and females approximately equally. More common in people of European descent.

Getting Involved in Clinical Trials

Clinical trials for MSA are evaluating neuroprotective therapies, anti-inflammatory agents, and approaches targeting alpha-synuclein pathology. The Multiple System Atrophy Coalition and patient registries maintain trial information. Early diagnosis through clinical assessment and MRI findings is important. Genetic counseling is typically not indicated as MSA is sporadic (not inherited). Multidisciplinary care including neurology, autonomic medicine, physical therapy, and symptomatic management optimize quality of life and safety.

Trusted Sources

Active Clinical Trials for Multiple System Atrophy

Finding trials for Multiple System Atrophy...

Related Neurological & Neuromuscular Conditions

Neurological & Neuromuscular

Duchenne Muscular Dystrophy

Duchenne muscular dystrophy is an X-linked genetic disorder causing progressive muscle weakness and degeneration, beginn...

Neurological & Neuromuscular

Spinal Muscular Atrophy

Spinal muscular atrophy is an autosomal recessive genetic disorder affecting motor neurons in the spinal cord, causing p...

Neurological & Neuromuscular

Myasthenia Gravis

Myasthenia gravis is a chronic autoimmune neuromuscular disorder causing muscle weakness and rapid fatigue. Antibodies a...